dasatinib / Generic mfg. - LARVOL DELTA

Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B. (PubMed, PLoS One) - "This research elucidates potential molecular targets, signaling pathways, and promising small molecule compounds that could aid in the treatment of chronic HBV infection and COVID-19."

Journal • Hepatitis B • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CDK1 • E2F7 • E2F8 • GZMA • KIF20A • TYMS

Real-world data vs pivotal trial outcomes of imatinib in newly diagnosed chronic myeloid leukemia patients. (ASCO 2025) - "Findings on patient demographics and treatment outcomes were compared to the IRIS trial, which demonstrated imatinib's superiority over interferon alfa plus cytarabine. The imatinib arms from pivotal trials of dasatinib (DASISION), nilotinib (ENESTnd), bosutinib (BFORE), and asciminib (ASC4FIRST) were also included in the trial cohort... Significant differences in patient demographics, risk profiles, and treatment outcomes were observed between RWD and trial cohorts. Despite lower rates of CCyR and MMR in RWD, long-term survival outcomes were similar across both groups. These findings underscore the importance of RWD in evaluating treatment effectiveness and highlight the need for increased diversity in clinical trial populations to ensure broader applicability of clinical findings."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1

Outcomes of veterans diagnosed with chronic myeloid leukemia in the tyrosine kinase inhibitor era. (ASCO 2025) - "The risk of bleeding was highest among patients treated with dasatinib, HR 1.46 (95% CI 1.21-1.90) compared to patients treated with imatinib. Bleeding risk was also elevated in patients who received nilotinib when compared to those treated with imatinib, HR 1.06 (95% CI 0.75-1.51)... Our analysis demonstrated worse overall survival among patients diagnosed with CML compared to a control group in a time where TKIs became the standard of care. We also showed increased rates of arterial thrombosis and bleeding associated with 2nd generation TKIs compared to imatinib. Hazard ratios (with 95% CI in parentheses) comparing rates of arterial thrombosis and bleeding among patients treated with 2nd generation TKIs to those treated with imatinib (n=2828)."

Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Thrombosis • ABL1 • BCR

Comparative effectiveness of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review and frequentist network meta-analysis. (ASCO 2025) - "Search terms included combinations of "Imatinib," "Dasatinib," "Nilotinib," "Bosutinib," "Ponatinib," and "Asciminib," along with "Chronic Myeloid Leukemia." A total of 176 studies were identified, with the inclusion criteria being met by 25 trials included after screening. This network meta-analysis highlights the superior efficacy of newer-generation TKIs, particularly Asciminib and Bosutinib, in achieving major molecular response at 12 months compared to Imatinib in chronic myeloid leukemia. These findings support the potential of second-and third-generation TKIs as more effective treatment options for CML."

HEOR • Retrospective data • Review • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

Real world evidence on treatment efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. (ASCO 2025) - "Imatinib was the most frequently utilized medication accounting for 54.9% of MMRs, followed by dasatinib (24.7%), nilotinib (15.9%) and finally bosutinib and asciminib each accounting for 1.8% of achieved MMRs. This report highlights a high response rate among our patients with 85% achieving complete response within the first 6 months with an acceptable side effect profile. A loss of reponse is observed at the 12 month mark which could be attributed to the use of imatinib in patients with high risk disease."

Clinical • HEOR • Real-world • Real-world evidence • Anemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia • ABL1 • BCR

Comparative clinical and molecular outcomes of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A comprehensive Bayesian network meta-analysis. (ASCO 2025) - "Dasatinib (%MD = 16.74, CrI: 7.51–25.47, SUCRA: 54.02) and Bosutinib (%MD = 6.31, CrI: -3.79 to 16.77, SUCRA: 22.72) were less effective. Our findings demonstrated Asciminib, Ponatinib, and Nilotinib as the most effective TKIs for improving (%) MMR and (%) CCR while minimizing anemia, neutropenia, and thrombocytopenia risks. Dasatinib demonstrated higher toxicity risks, and Imatinib ranked lowest in efficacy and safety, thereby reaffirming the value of newer TKIs in managing CML."

Retrospective data • Anemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia • ABL1 • BCR

Investigating the efficacy and safety of ponatinib in acute lymphoblastic leukemia: A systematic review. (ASCO 2025) - "In particular, the average 3-year OS rates of ponatinib compared to imatinib was 98% vs 58% respectively; the average 3-year OS of ponatinib vs dasatinib was 87.5% vs 46.5% respectively. Ponatinib exhibits promising response rates for Ph+ ALL patients, especially when combined with chemotherapy and allo-SCT, as well as superior overall survival rates compared to earlier generation TKIs."

Clinical • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

Efficacy of low-dose dasatinib (50mg) in chronic myeloid leukemia: Chronic phase (CML-CP) in LMIC—Are we there yet? (ASCO 2025) - "Although limited by its small sample size, our study contributes to the existing body of evidence of low-dose Dasatinib( 50mg OD). Notably, no cases of cardiac or pulmonary toxicity were observed in our study. These findings suggest the potential for dose individualization, optimizing therapeutic outcomes while minimizing toxicity."

Clinical • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pulmonary Disease • Respiratory Diseases • ABL1 • BCR

Outcomes of Ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies. (ASCO 2025) - "The remaining 20% of pts received novel therapies in first-line setting, including C10403 + inotuzumab (InO) in 7%, ino + blinatumomab (blin) in 6%, hyperCVD + venetoclax in 4% and C10403 + imatinib in 3%...Of note, 5 pts received kinase inhibitors (ruxolutinib, dasatinib, imatinib) in salvage setting, but did not achieve remission... Ph-like B-ALL pts treated with standard chemo have lower CR and RFS rates. Adding novel agents (InO, blin, venetoclax) to upfront regimens may improve outcomes. Future studies should focus on optimal first-line combinations and higher-risk groups such as KRAS-mutated Ph-like B-ALL."

IO biomarker • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • ABL2 • CDKN2A • CRLF2 • CSF1R • FGFR • IKZF1 • JAK2 • KRAS • NRAS • PAX5 • ROS1

Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial. (ASCO 2025) - P2 | "Prior treatment (Tx) included dasatinib (44.6%), imatinib (42.6%), nilotinib (9.9%), or bosutinib (5.0%); 66.3% of pts had received prior Tx for ≥12 mo. 2L ASC demonstrated high molecular response rates at wk 24 and safety consistent with previously established ASC data across Tx lines; no new or worsening safety signals arose. ASC was tolerable with few AEs leading to discontinuation. These IA results support ASC as a Tx option in 2L CML-CP."

Clinical • P2 data • Cardiovascular • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Neutropenia • Oncology • Pain • Thrombocytopenia

Early predictors of treatment-free remission in chronic myeloid leukemia. (ASCO 2025) - "TKI usage also differed (P = 0.01), with 32% vs. 41% receiving imatinib, 43% vs. 33% dasatinib, 19% receiving nilotinib in both groups, and 6% vs. 8% receiving ponatinib. Early predictors of TFR eligibility include older age, halving-time <30 days, MMR at 1 year, and the e14a2 transcript. These factors could guide prospective trial designs as early surrogates for TFR."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults. (ASCO 2025) - P1 | "Dual ABL1 inhibition with ASC and DAS can be safely combined with blin in Ph+ acute leukemia. An additional 25-pt cohort is planned with blin in combination with DAS and ASC at optimized doses. Response kinetics."

Clinical • Combination therapy • P1 data • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Respiratory Diseases • IKZF1

CHRONIC MYELOID LEUKEMIA MONITORING EXPERIENCE IN ECUADOR, SOLCA - GUAYAQUIL (2015-2024) (EHA 2025) - "The number of tests performed to each case ranged from a single one up to 22 during this period.Of 377, 207 (55%) used a first generation TKI (IMATINIB) of which 163/207(78.7%) had no response (NR), 33/207(16%) reached MR3 and 11/207 (5.3%) MR4.5; 158/377(41.9%) used a second generation TKI (2G) (NILOTINIB/DASATINIB/BOSUTINIB) showing NR in 78/158 cases (49.4%), 60/158 (38%) MR3 and 20/158(12.6%) MR4.5. During 9 years we have performed 2238 qPCR detecting BCR::ABL chimeric transcript to 414 patients diagnosed as CML. Most of the cases presented the fusion transcript b2a2/b3a2. The patients treated with IMATINIB had a high NR (78.7%) than TKI-2G (42%)."

Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • ABL1

INOTUZUMAB-BASED PROTOCOLS ARE SAFE AND EFFECTIVE IN PATIENTS WITH RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA PLANNED FOR CD19 CAR-T CELL THERAPY. (EHA 2025) - "In Ph positive ALL (n=9/32), the use of tyrosine kinase inhibitors was allowed (Ponatinib- 80%(4/5), Dasatinib- 20%(1/5)). Inotuzumab-based regimen is safe and effective and enhances the feasibility of receiving tali-cel. Such optimal usage of targeted therapies can obviate the need for alloSCT as consolidation."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Hepatology • Infectious Disease • Inflammation • Leukemia • Oncology

IMPACT OF ADVERSE EVENTS ON QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA (CML) - RESULTS FROM THE PATIENT SURVEY ON HUMANISTIC BURDEN OF INTOLERANCE TO FIRST OR SECOND TKIS (SHIFT) STUDY IN THE US (EHA 2025) - "TKIs utilized included imatinib (34%), dasatinib (37%), bosutinib (14%), nilotinib (12%), or ponatinib (3%).Patients reported a median of 3 AEs (range: 0-14) in the last 7 days. Findings from the SHIFT study demonstrate the substantial humanistic burden of TKI-related AEs among patients with CML in the US. Most patients had multiple persistent AEs, negatively impacting physical and mental health, contributing to worse QoL. In addition, the extent of work productivity impairment is reflected in the high proportion modifying employment due to CML and, among those employed, experiencing some work productivity loss."

Adverse events • Clinical • HEOR • Chronic Myeloid Leukemia • Fatigue • Hematological Malignancies • Leukemia • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Orthopedics • Pain • Psychiatry

THE STUDY ON THE EFFECTS AND MECHANISMS OF TYROSINE KINASE INHIBITORS ON THE FUNCTION OF CD19 CAR-T CELLS (EHA 2025) - "CAR-T cells and B-ALL cells co-cultured killing cytotoxicity experiments found that high concentrations of Imatinib(IM), Nilotinib(NL), Dasatinib(DS), and Ponatinib(PN) reduced the ability of CAR-T cells to target and kill tumors, the level of degranulation, and the secretion of CKs during the killing process. TKIs in the higher concentration range could inhibit the proliferation of CAR-T cells significantly, but they have a limited effect on promoting apoptosis. DS and PN reduced the proportion of CD8+ cells and TTE cells in CAR-T cells. It can slightly inhibit the anti-tumor ability of CAR-T cells and reduce the CK release level at the same time, but DS and PN in mice retained their tumor-cytotoxic effect while reducing the secretion of CK."

CAR T-Cell Therapy • IO biomarker • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD8 • TNFRSF10B

ASSESSMENT OF TRANSITIONING FROM HIGH-POTENCY TO LOW-POTENCY INHIBITORS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: THE DOWNGRADING-IMPACT (D-IMPACT) PROJECT, A CML CAMPUS STUDY (EHA 2025) - "TKIs before downgrading: Nilotinib (NIL) (n=73; 46%), Dasatinib (DAS) (n=60; 38%), Ponatinib (n=17; 11%), Bosutinib (BOS) (n=6; 4%), Asciminib (n=1; 1%)...The TKIs used for downgrading were imatinib (IMA) 106 (67.5%), Bosutinib 40 (25.5%), Nilotinib 4 (2.5%), Dasatinib 1(0.6%), Asciminib 5 (3.3%), Interferon 1 (0.6%) (Fig1A)... This exploratory study shows that a downgrading approach can be strategic and safely considered in CML patients, especially for long-term treatment maintaining therapeutic efficacy without adverse clinical outcomes."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1

FIRST-IN-HUMAN STUDY OF ASCIMINIB (ASC) MONOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) (EHA 2025) - P1, P2 | "Pts were heavily pretreated: 89.3% (n=25) had ≥2 prior TKIs, 53.6% (n=15) had prior ponatinib treatment, and 46.4% (n=13) had relapse post transplant. In the current analysis, ASC monotherapy in heavily pretreated pts with Ph+ ALL demonstrated antileukemic activity and was well tolerated, with favorable safety, consistent with parallel studies of ASC in pts with CML. Additional phase 1 cohorts showed that dual treatment with ASC and dasatinib is safe for pts with Ph+ ALL. Ongoing trials are exploring the combination of ASC and blinatumomab (NCT06308588) and ASC with dasatinib, blinatumomab, and steroids (NCT03595917)."

Clinical • Monotherapy • P1 data • Acute Lymphocytic Leukemia • Anemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia

CHALLENGES IN TREATING CML PATIENTS IN LOW INCOME COUNTRIES: A SINGLE CENTRE EXPERIENCE (EHA 2025) - "Therapy modification was required in 21% of cases, with 12.6% switching from imatinib to dasatinib due to suboptimal response and 8.4% due to drug intolerance. Additionally, 2.5% of dasatinib-treated patients were switched to nilotinib, 1.7% to bosutinib, and 1.7% to ponatinib... Despite the availability of generic first-generation TKIs, 7.75% of patients did not initiate therapy, indicating barriers to treatment access and adherence. The observed suboptimal response rates were higher than reported in the literature, likely due to poor drug adherence and irregular supply of TKIs in government healthcare settings. Addressing these challenges is essential to improving treatment outcomes and bridging the disparity in CML management in developing nations."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

VENETOCLAX IN COMBINATION WITH CYTARABINE AND ACTINOMYCIN D (ACTIVE) FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (EHA 2025) - "Venetoclax exposure was confirmed in 13% (14/107) of cases, and 25 % (26/107) had relapsed after a previous alloSCT.Gilteritinib, trametinib, ivosidenib, ponatinib, and dasatinib were added to ACTIVE in 22 % (23/107), 4 % (4/107), 2 % (2/107), 1 % (1/107), and 1 % (1/107), respectively.The ORR was 78 % (82/105), and the CRc rate was 62 % (65/105) with 45 % (29/65) achieving MRD negativity. ACTIVE-based salvage treatment demonstrates promissing antileukemic efficacy with a high bridge-to-alloSCT rate in R/R AML."

Combination therapy • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology

TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DE NOVO ACCELERATED-PHASE AND/OR TYROSINE KINASE-INHIBITOR FAILURE: A RETROSPECTIVE MULTICENTER STUDY (EHA 2025) - "51 (86%) received front-line imatinib; 8 (14%), nilotinib. Before TKI cessation, 36 (61%) switched to 2-lines or 3-lines TKI therapy; 21 received nilotinib; 12, dasatinib; 2, ponatinib; one, flumatinib... We concluded that patients who have been diagnosed with CML-AP at presentation or have a history of TKI failure can pursue TFR after meeting the criteria of discontinuation. Age at discontinuation 0.1% at 12 month on TKI therapy were associated with higher probability of loss of MMR."

Retrospective data • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1

REAL-WORLD TREATMENT PATTERNS OF TYROSINE KINASE INHIBITORS IN KOREAN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (EHA 2025) - "Approval of nilotinib and radotinib (2012) for reimbursement in Korea led to a shift in treatment patterns between 2012-2017. These results provide insights on treatment decision-making and choosing the optimal TKI sequence in pts with CML based in Korea, taking into account the unique treatment landscape."

Clinical • HEOR • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Oncology • Pulmonary Disease • Respiratory Diseases

DISCONTINUING TKIS IN CML PATIENTS LACKING DEEP MOLECULAR RESPONSE: RISK OR OPPORTUNITY? AN EXPLORATORY STUDY FROM THE ITALY-TFR REGISTRY (EHA 2025) - P=N/A | "Twenty-three pts (59%) had to resume therapy (Fig.1), median time to restart treatment for these pts was 7.36 mos (IQR: 3.49 - 10.5).Pts who had to restart therapy were 9 treated with imatinib, 3 with nilotinib, 7 with dasatinib, 3 with bosutinib, 1 with ponatinib (12 pts stopped TKI in frontline, 11 pts in 2nd or further lines). Our population is heterogeneous and worthy of more detailed analysis to better understand which characteristics make the outcome so favorable in this unexpected population. Duration of TKI treatment before stopping could be a potential predictor of successful TFR also in pts lacking DMR."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

DE-ESCALATION AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS RECEIVING SALVAGE THERAPY FOR RESISTANCE, WARNING OR LACK OF DEEP MOLECULAR RESPONSE (EHA 2025) - "Imatinib was the 1st line TKI in all but one pt who received nilotinib...Last TKI prior to discontinuation was a 2nd generation drug (dasatinib, nilotinib or bosutinib) in 88% of pts, a 3rd generation compound (ponatinib) in 7% of pts and the allosteric TKI asciminib in 2% of pts... TKI discontinuation is pts with prior history of resistance, warning or lack of DMR appears feasible and safe in our experience. A larger series is required to draw firm conclusions, but our results pave the way for recommendations in clinical practice. Maintenance of a DMR after therapy de-escalation might identify pts with high probabilities of TFR success."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1

ACHIEVING TREATMENT FREE REMISSION IN CML PATIENTS TREATED WITH BOSUTINIB: DATA FROM THE ITALY-TFR REGISTRY (EHA 2025) - P=N/A, P3 | "While TKI discontinuation has become clinical practice for patients (pts) treated frontline with imatinib, nilotinib and dasatinib who achieve a stable deep molecular response (DMR), data on bosutinib discontinuation are more limited and further studies are needed to assess its potential for treatment free remission (TFR). In fact only a single center study focusing on ponatinib and bosutinib discontinuation is reported, which includes 8 pts who discontinued bosutinib mostly due to toxicity...One patient restarted bosutinib, 1 patient started asciminib, 1 patient nilotinib and 1 patient imatinib... Our preliminary analysis suggests that discontinuing Bosutinib is as safe as discontinuing other TKIs, confirming the single center experience reported in literature. Our patients suspended by clinical decision rather than toxicity. The depth of molecular response was the strongest predictor of successful TFR for the cases already reported in literature."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology